Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials

Gadolinium enhancement is often used in randomized clinical trials to evaluate the efficacy of new drugs in multiple sclerosis (MS). Knowledge about predictors of enhancement status is important for the selection of patients for MRI monitored trials. Data from 17 trials were available in anonymized...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neurology 2005-11, Vol.65 (9), p.1447-1454
Hauptverfasser:	BARKHOF, F, HELD, U, MILLER, D. H, PETKAU, J, WOLINSKY, J, SIMON, J. H, DAUMER, M, FAZEKAS, F, FILIPPI, M, FRANK, J. A, KAPPOS, L, LI, D, MENZLER, S
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Age of Onset Biological and medical sciences Brain - drug effects Brain - pathology Brain - physiopathology Causality Diagnosis, Differential Disability Evaluation Female Gadolinium Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy Humans Magnetic Resonance Imaging - standards Male Medical sciences Multiple Sclerosis - diagnosis Multiple Sclerosis - drug therapy Multiple Sclerosis - physiopathology Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Multivariate Analysis Nerve Fibers, Myelinated - pathology Nervous system (semeiology, syndromes) Neurology Odds Ratio Patient Selection Predictive Value of Tests Randomized Controlled Trials as Topic - standards Recurrence Reproducibility of Results Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!